183 related articles for article (PubMed ID: 9703446)
1. Effect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J; Mills KR
Muscle Nerve; 1998 Sep; 21(9):1196-8. PubMed ID: 9703446
[TBL] [Abstract][Full Text] [Related]
2. Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J; Mills KR
J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):213-7. PubMed ID: 9703174
[TBL] [Abstract][Full Text] [Related]
3. Decay of postexercise augmentation in the Lambert-Eaton myasthenic syndrome: effect of cooling.
Maddison P; Newsom-Davis J; Mills KR
Neurology; 1998 Apr; 50(4):1083-7. PubMed ID: 9566398
[TBL] [Abstract][Full Text] [Related]
4. 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.
Molgó J; Guglielmi JM
Pflugers Arch; 1996; 431(6 Suppl 2):R295-6. PubMed ID: 8739381
[TBL] [Abstract][Full Text] [Related]
5. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.
Lundh H; Nilsson O; Rosén I; Johansson S
Acta Neurol Scand; 1993 Aug; 88(2):136-40. PubMed ID: 8213058
[TBL] [Abstract][Full Text] [Related]
6. Treatment for Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J
Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
[TBL] [Abstract][Full Text] [Related]
7. Treatment for Lambert-Eaton myasthenic syndrome.
Keogh M; Sedehizadeh S; Maddison P
Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD003279. PubMed ID: 21328260
[TBL] [Abstract][Full Text] [Related]
8. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
Wirtz PW; Titulaer MJ; Gerven JM; Verschuuren JJ
Expert Rev Clin Immunol; 2010 Nov; 6(6):867-74. PubMed ID: 20979551
[TBL] [Abstract][Full Text] [Related]
9. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
Sanders DB
Ann N Y Acad Sci; 1998 May; 841():811-6. PubMed ID: 9668334
[No Abstract] [Full Text] [Related]
10. Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine.
Chan KY; Chang RS; Lau VW; Chan ML; Lai T
Ann Palliat Med; 2016 Oct; 5(4):311-314. PubMed ID: 27506750
[TBL] [Abstract][Full Text] [Related]
11. Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome before and after 3,4-diaminopyridine.
Sadeh M; River Y; Argov Z
Muscle Nerve; 1997 Jun; 20(6):735-9. PubMed ID: 9149081
[TBL] [Abstract][Full Text] [Related]
12. 3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials.
Zhang N; Hong D; Ouyang T; Meng W; Huang J; Li M; Hong T
BMC Neurol; 2021 Sep; 21(1):371. PubMed ID: 34563155
[TBL] [Abstract][Full Text] [Related]
13. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
Quartel A; Turbeville S; Lounsbury D
Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
[TBL] [Abstract][Full Text] [Related]
14. 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.
Oh SJ; Claussen GG; Hatanaka Y; Morgan MB
Muscle Nerve; 2009 Nov; 40(5):795-800. PubMed ID: 19722254
[TBL] [Abstract][Full Text] [Related]
15. Single-fiber electromyography improvement with 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
Kim DS; Claussen GC; Oh SJ
Muscle Nerve; 1998 Aug; 21(8):1107-8. PubMed ID: 9655139
[No Abstract] [Full Text] [Related]
16. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.
McEvoy KM; Windebank AJ; Daube JR; Low PA
N Engl J Med; 1989 Dec; 321(23):1567-71. PubMed ID: 2555713
[TBL] [Abstract][Full Text] [Related]
17. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma.
Chalk CH; Murray NM; Newsom-Davis J; O'Neill JH; Spiro SG
Neurology; 1990 Oct; 40(10):1552-6. PubMed ID: 2170866
[TBL] [Abstract][Full Text] [Related]
18. Amifampridine to treat Lambert-Eaton myasthenic syndrome.
Oh SJ
Drugs Today (Barc); 2020 Oct; 56(10):623-641. PubMed ID: 33185628
[TBL] [Abstract][Full Text] [Related]
19. 3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis.
Sanders DB; Howard JF; Massey JM
Ann N Y Acad Sci; 1993 Jun; 681():588-90. PubMed ID: 8357206
[No Abstract] [Full Text] [Related]
20. Neurogenic bladder in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.
Satoh K; Motomura M; Suzu H; Nakao Y; Fujimoto T; Fukuda T; Nakane S; Nakamura T; Eguchi K
J Neurol Sci; 2001 Jan; 183(1):1-4. PubMed ID: 11166786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
